JP2013512678A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512678A5 JP2013512678A5 JP2012542240A JP2012542240A JP2013512678A5 JP 2013512678 A5 JP2013512678 A5 JP 2013512678A5 JP 2012542240 A JP2012542240 A JP 2012542240A JP 2012542240 A JP2012542240 A JP 2012542240A JP 2013512678 A5 JP2013512678 A5 JP 2013512678A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- factor viii
- amino acids
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 159
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 130
- 229920001184 polypeptide Polymers 0.000 claims description 129
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 129
- 108010054218 Factor VIII Proteins 0.000 claims description 114
- 102000001690 Factor VIII Human genes 0.000 claims description 114
- 229960000301 factor viii Drugs 0.000 claims description 114
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 58
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 30
- 208000032843 Hemorrhage Diseases 0.000 claims description 26
- 208000034158 bleeding Diseases 0.000 claims description 26
- 230000000740 bleeding effect Effects 0.000 claims description 26
- 238000001356 surgical procedure Methods 0.000 claims description 21
- 238000011287 therapeutic dose Methods 0.000 claims description 21
- 238000011084 recovery Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 5
- 238000007917 intracranial administration Methods 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 208000029836 Inguinal Hernia Diseases 0.000 claims description 3
- 210000000683 abdominal cavity Anatomy 0.000 claims description 3
- 238000007428 craniotomy Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000013150 knee replacement Methods 0.000 claims description 3
- 238000002271 resection Methods 0.000 claims description 3
- 238000007483 tonsillectomy Methods 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000002297 emergency surgery Methods 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 88
- 108010076504 Protein Sorting Signals Proteins 0.000 description 43
- 108010014173 Factor X Proteins 0.000 description 21
- 108090001015 cancer procoagulant Proteins 0.000 description 15
- 108010048049 Factor IXa Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 3
- 102000057593 human F8 Human genes 0.000 description 3
- 229960000900 human factor viii Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010072043 Central nervous system haemorrhage Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010028024 Mouth haemorrhage Diseases 0.000 description 2
- 206010028309 Muscle haemorrhage Diseases 0.000 description 2
- 208000009613 Oral Hemorrhage Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 210000000574 retroperitoneal space Anatomy 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26707009P | 2009-12-06 | 2009-12-06 | |
| US61/267,070 | 2009-12-06 | ||
| US28505409P | 2009-12-09 | 2009-12-09 | |
| US61/285,054 | 2009-12-09 | ||
| US30159210P | 2010-02-04 | 2010-02-04 | |
| US61/301,592 | 2010-02-04 | ||
| US36306510P | 2010-07-09 | 2010-07-09 | |
| US61/363,065 | 2010-07-09 | ||
| US37311310P | 2010-08-12 | 2010-08-12 | |
| US61/373,113 | 2010-08-12 | ||
| US41092910P | 2010-11-07 | 2010-11-07 | |
| US61/410,929 | 2010-11-07 | ||
| US41967610P | 2010-12-03 | 2010-12-03 | |
| US61/419,676 | 2010-12-03 | ||
| PCT/US2010/059136 WO2011069164A2 (en) | 2009-12-06 | 2010-12-06 | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012409A Division JP6062459B2 (ja) | 2009-12-06 | 2015-01-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512678A JP2013512678A (ja) | 2013-04-18 |
| JP2013512678A5 true JP2013512678A5 (enExample) | 2013-12-26 |
| JP5903048B2 JP5903048B2 (ja) | 2016-04-13 |
Family
ID=44115536
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542240A Active JP5903048B2 (ja) | 2009-12-06 | 2010-12-06 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2015012409A Active JP6062459B2 (ja) | 2009-12-06 | 2015-01-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2016209535A Active JP6385410B2 (ja) | 2009-12-06 | 2016-10-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2017220060A Active JP6641340B2 (ja) | 2009-12-06 | 2017-11-15 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2019202433A Withdrawn JP2020019821A (ja) | 2009-12-06 | 2019-11-07 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2022020759A Active JP7244688B2 (ja) | 2009-12-06 | 2022-02-14 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2023036392A Pending JP2023071969A (ja) | 2009-12-06 | 2023-03-09 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2025037046A Pending JP2025083451A (ja) | 2009-12-06 | 2025-03-10 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012409A Active JP6062459B2 (ja) | 2009-12-06 | 2015-01-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2016209535A Active JP6385410B2 (ja) | 2009-12-06 | 2016-10-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2017220060A Active JP6641340B2 (ja) | 2009-12-06 | 2017-11-15 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2019202433A Withdrawn JP2020019821A (ja) | 2009-12-06 | 2019-11-07 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2022020759A Active JP7244688B2 (ja) | 2009-12-06 | 2022-02-14 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2023036392A Pending JP2023071969A (ja) | 2009-12-06 | 2023-03-09 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2025037046A Pending JP2025083451A (ja) | 2009-12-06 | 2025-03-10 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9050318B2 (enExample) |
| EP (4) | EP4382170A3 (enExample) |
| JP (8) | JP5903048B2 (enExample) |
| KR (1) | KR101770849B1 (enExample) |
| CN (1) | CN102791285A (enExample) |
| AU (6) | AU2010325787B2 (enExample) |
| BR (1) | BR112012013502A2 (enExample) |
| CA (2) | CA3121739A1 (enExample) |
| CO (1) | CO6561782A2 (enExample) |
| CY (2) | CY1119919T1 (enExample) |
| DK (1) | DK2506868T3 (enExample) |
| EA (2) | EA025416B1 (enExample) |
| ES (2) | ES2659888T3 (enExample) |
| HR (2) | HRP20180135T1 (enExample) |
| HU (1) | HUE036233T2 (enExample) |
| IL (2) | IL220204B (enExample) |
| LT (1) | LT2506868T (enExample) |
| ME (1) | ME02964B (enExample) |
| MX (3) | MX353233B (enExample) |
| MY (1) | MY159135A (enExample) |
| NO (1) | NO2506868T3 (enExample) |
| NZ (2) | NZ600709A (enExample) |
| PL (2) | PL3326643T3 (enExample) |
| PT (2) | PT3326643T (enExample) |
| RS (1) | RS56957B1 (enExample) |
| SG (3) | SG10201408049SA (enExample) |
| SI (1) | SI2506868T1 (enExample) |
| SM (1) | SMT201800099T1 (enExample) |
| WO (1) | WO2011069164A2 (enExample) |
| ZA (1) | ZA201204874B (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| BR112012004094A2 (pt) | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
| MX353233B (es) * | 2009-12-06 | 2018-01-08 | Bioverativ Therapeutics Inc | Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. |
| WO2012006635A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Processable single chain molecules and polypeptides made using same |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| DK2717898T3 (en) | 2011-06-10 | 2019-03-25 | Bioverativ Therapeutics Inc | COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF |
| DK3513804T3 (da) | 2011-07-08 | 2022-06-20 | Bioverativ Therapeutics Inc | Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf |
| US10656167B2 (en) | 2011-07-25 | 2020-05-19 | Bioverativ Therapeutics Inc. | Assays to monitor bleeding disorders |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| PL3453402T3 (pl) * | 2012-01-12 | 2022-03-21 | Bioverativ Therapeutics Inc. | Zmniejszenie immunogenności przeciwko czynnikowi viii u osób poddawanych terapii czynnikiem viii |
| EA035323B1 (ru) * | 2012-01-12 | 2020-05-28 | Биовератив Терапьютикс Инк. | Полипептиды химерного фактора viii и их применение |
| LT2822577T (lt) | 2012-02-15 | 2019-03-25 | Bioverativ Therapeutics Inc. | Rekombinantiniai faktoriaus viii baltymai |
| HRP20221531T1 (hr) * | 2012-02-15 | 2023-02-17 | Bioverativ Therapeutics Inc. | Pripravci faktora viii i postupci dobivanja i korištenja istih |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP2836518B1 (en) | 2012-04-11 | 2019-01-02 | Bioverativ Therapeutics Inc. | Methods of detecting glycosaminoglycans |
| CA2875246A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
| AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
| WO2014008480A2 (en) * | 2012-07-06 | 2014-01-09 | Biogen Idec Ma Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
| US10138291B2 (en) * | 2012-07-11 | 2018-11-27 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
| EP3970738A1 (en) | 2012-07-25 | 2022-03-23 | Bioverativ Therapeutics Inc. | Blood factor monitoring assay and uses thereof |
| CA2888806A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
| HK1214539A1 (zh) * | 2012-10-30 | 2016-07-29 | Bioverativ Therapeutics Inc. | 應用viii因子多肽的方法 |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
| LT2956477T (lt) * | 2013-02-15 | 2021-02-10 | Bioverativ Therapeutics Inc. | Optimizuotas faktoriaus viii genas |
| US9090697B2 (en) * | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| PL3666283T3 (pl) * | 2013-03-15 | 2022-10-03 | Bioverativ Therapeutics Inc. | Formulacje polipeptydu czynnika viii |
| EP3003368A4 (en) | 2013-05-24 | 2017-05-03 | Biogen MA Inc. | Anti-gpiib/iiia antibodies or uses thereof |
| TW201536811A (zh) * | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途 |
| JP2016526542A (ja) * | 2013-06-20 | 2016-09-05 | バクスアルタ インコーポレイティッド | 薬物動態学的な薬剤投与計画の装置および方法 |
| WO2014210547A1 (en) * | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker |
| WO2014210558A1 (en) * | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker with xten and its uses thereof |
| CA2919583C (en) | 2013-07-31 | 2018-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| US20160311885A1 (en) | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
| HUE057005T2 (hu) | 2013-09-25 | 2022-04-28 | Bioverativ Therapeutics Inc | Oszlopon történõ vírusinaktiváló eljárások |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| WO2015070014A1 (en) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Procoagulant fusion compound |
| EP3082848B1 (en) * | 2013-12-06 | 2023-10-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| US20160289633A1 (en) | 2013-12-20 | 2016-10-06 | Biogen Ma Inc. | Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality |
| DK3091997T5 (da) | 2014-01-10 | 2024-10-14 | Bioverativ Therapeutics Inc | Kimære faktor viii-proteiner og anvendelser deraf |
| KR102382402B1 (ko) | 2014-02-04 | 2022-04-01 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도 |
| WO2015148454A1 (en) * | 2014-03-28 | 2015-10-01 | Asklepios Biopharmaceutical, Inc. | Optimized and modified factor viii genes for gene therapy |
| SI3134127T1 (sl) | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
| EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
| EP3207130B1 (en) | 2014-10-14 | 2019-08-07 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| US11560418B2 (en) | 2015-10-20 | 2023-01-24 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor IX fusion proteins |
| PL3411478T3 (pl) | 2016-02-01 | 2022-10-03 | Bioverativ Therapeutics Inc. | Geny zoptymalizowanego czynnika VIII |
| SG11201808475XA (en) | 2016-04-15 | 2018-10-30 | Baxalta Inc | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
| TW201739448A (zh) * | 2016-05-06 | 2017-11-16 | 安成生物科技股份有限公司 | 用於治療及/或預防血液相關疾病之方法及配方 |
| JP6877469B2 (ja) * | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用 |
| SG11201900027XA (en) | 2016-08-05 | 2019-02-27 | Medimmune Llc | Anti-o2 antibodies and uses thereof |
| CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技（上海）有限公司 | 双特异性抗体及其制备方法与用途 |
| CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| WO2018075375A1 (en) | 2016-10-19 | 2018-04-26 | Medimmune, Llc | Anti-o1 antibodies and uses thereof |
| BR112019011198A2 (pt) * | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| CN108239151B (zh) * | 2016-12-23 | 2020-07-03 | 海门晟斯生物制药有限公司 | 重组单链人FVIII-Fc融合蛋白及其应用 |
| US10896749B2 (en) * | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
| RS66972B1 (sr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc | Metode lečenja hemofilije a |
| MX2020013036A (es) | 2018-06-05 | 2021-02-26 | Amgen Inc | Modulacion de la fagocitosis celular dependiente de anticuerpos. |
| US20220033511A1 (en) | 2018-09-11 | 2022-02-03 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
| BR112021010047A2 (pt) | 2018-12-06 | 2021-08-24 | Bioverativ Therapeutics Inc. | Uso de vetores lentivirais expressando o fator ix |
| CN114007637A (zh) | 2019-06-19 | 2022-02-01 | 比奥维拉迪维治疗股份有限公司 | 用于治疗血友病和低骨矿物质密度的重组因子viii-fc |
| CN115279896A (zh) | 2019-09-30 | 2022-11-01 | 比奥维拉迪维治疗股份有限公司 | 慢病毒载体配制品 |
| MX2023000156A (es) | 2020-06-24 | 2023-02-16 | Bioverativ Therapeutics Inc | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. |
| PE20251064A1 (es) * | 2022-04-28 | 2025-04-09 | Biocad Joint Stock Co | Acido nucleico aislado que codifica una proteina de fusion basada en fviii-bdd y en un peptido senal heterologo, y uso de la misma |
| CN114989307B (zh) * | 2022-05-11 | 2023-08-01 | 华兰生物工程股份有限公司 | 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235881A (en) * | 1978-12-04 | 1980-11-25 | Cort Joseph H | Method for producing high potency factor VIII |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| JPH0788399B2 (ja) | 1985-04-12 | 1995-09-27 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新規プロコアギュラント蛋白質 |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| EP0253870B1 (en) | 1986-01-03 | 1993-03-31 | Genetics Institute, Inc. | Method for producing factor viii:c-type proteins |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ATE386538T1 (de) * | 2001-02-05 | 2008-03-15 | Novo Nordisk Healthcare Ag | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| EP1444986A1 (en) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| DE602004031390D1 (de) * | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| EP1644039B1 (en) * | 2003-06-19 | 2014-10-01 | Genentech, Inc. | Compositions and methods for treating coagulation related disorders |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| SI1824988T1 (sl) | 2004-11-12 | 2017-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| NZ572050A (en) * | 2006-03-31 | 2011-09-30 | Baxter Int | Factor VIII conjugated to polyethylene glycol |
| EP3231440A1 (en) | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| ES2476690T3 (es) * | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| US8800831B2 (en) | 2009-08-19 | 2014-08-12 | Larry A. Gray | Multi-purpose rack and method thereof |
| WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| CN102427823A (zh) * | 2009-03-24 | 2012-04-25 | 拜耳医药保健有限公司 | 因子viii变体及使用方法 |
| GB0908515D0 (en) | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
| MX353233B (es) | 2009-12-06 | 2018-01-08 | Bioverativ Therapeutics Inc | Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. |
| DK3513804T3 (da) * | 2011-07-08 | 2022-06-20 | Bioverativ Therapeutics Inc | Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf |
| PL3453402T3 (pl) * | 2012-01-12 | 2022-03-21 | Bioverativ Therapeutics Inc. | Zmniejszenie immunogenności przeciwko czynnikowi viii u osób poddawanych terapii czynnikiem viii |
| PL3666283T3 (pl) * | 2013-03-15 | 2022-10-03 | Bioverativ Therapeutics Inc. | Formulacje polipeptydu czynnika viii |
| JP6083911B2 (ja) | 2014-12-19 | 2017-02-22 | 花王株式会社 | 吸収性物品 |
-
2010
- 2010-12-06 MX MX2016000039A patent/MX353233B/es unknown
- 2010-12-06 HU HUE10835255A patent/HUE036233T2/hu unknown
- 2010-12-06 EA EA201290443A patent/EA025416B1/ru not_active IP Right Cessation
- 2010-12-06 NO NO10835255A patent/NO2506868T3/no unknown
- 2010-12-06 ES ES10835255.0T patent/ES2659888T3/es active Active
- 2010-12-06 CN CN2010800629507A patent/CN102791285A/zh active Pending
- 2010-12-06 PL PL17194648T patent/PL3326643T3/pl unknown
- 2010-12-06 NZ NZ600709A patent/NZ600709A/en unknown
- 2010-12-06 WO PCT/US2010/059136 patent/WO2011069164A2/en not_active Ceased
- 2010-12-06 AU AU2010325787A patent/AU2010325787B2/en active Active
- 2010-12-06 PL PL10835255T patent/PL2506868T3/pl unknown
- 2010-12-06 MX MX2012006347A patent/MX336830B/es active IP Right Grant
- 2010-12-06 MY MYPI2012002429A patent/MY159135A/en unknown
- 2010-12-06 PT PT171946486T patent/PT3326643T/pt unknown
- 2010-12-06 JP JP2012542240A patent/JP5903048B2/ja active Active
- 2010-12-06 ES ES17194648T patent/ES2880038T3/es active Active
- 2010-12-06 NZ NZ703153A patent/NZ703153A/en unknown
- 2010-12-06 SG SG10201408049SA patent/SG10201408049SA/en unknown
- 2010-12-06 CA CA3121739A patent/CA3121739A1/en active Pending
- 2010-12-06 LT LTEP10835255.0T patent/LT2506868T/lt unknown
- 2010-12-06 HR HRP20180135TT patent/HRP20180135T1/hr unknown
- 2010-12-06 US US13/513,424 patent/US9050318B2/en active Active
- 2010-12-06 MX MX2018000089A patent/MX382693B/es unknown
- 2010-12-06 DK DK10835255.0T patent/DK2506868T3/da active
- 2010-12-06 ME MEP-2018-40A patent/ME02964B/me unknown
- 2010-12-06 EP EP24152910.6A patent/EP4382170A3/en active Pending
- 2010-12-06 PT PT108352550T patent/PT2506868T/pt unknown
- 2010-12-06 EA EA201691109A patent/EA038618B1/ru unknown
- 2010-12-06 KR KR1020127017595A patent/KR101770849B1/ko active Active
- 2010-12-06 RS RS20180182A patent/RS56957B1/sr unknown
- 2010-12-06 SG SG10201907152YA patent/SG10201907152YA/en unknown
- 2010-12-06 CA CA2782424A patent/CA2782424C/en active Active
- 2010-12-06 EP EP21161784.0A patent/EP3906937A1/en not_active Ceased
- 2010-12-06 SG SG2012039640A patent/SG181130A1/en unknown
- 2010-12-06 EP EP17194648.6A patent/EP3326643B1/en active Active
- 2010-12-06 SI SI201031628T patent/SI2506868T1/en unknown
- 2010-12-06 BR BR112012013502A patent/BR112012013502A2/pt not_active Application Discontinuation
- 2010-12-06 EP EP10835255.0A patent/EP2506868B1/en active Active
- 2010-12-06 SM SM20180099T patent/SMT201800099T1/it unknown
-
2012
- 2012-06-06 IL IL220204A patent/IL220204B/en active IP Right Grant
- 2012-06-29 CO CO12109855A patent/CO6561782A2/es unknown
- 2012-06-29 ZA ZA2012/04874A patent/ZA201204874B/en unknown
-
2013
- 2013-03-11 US US13/793,783 patent/US9241978B2/en active Active
-
2015
- 2015-01-26 JP JP2015012409A patent/JP6062459B2/ja active Active
- 2015-12-09 US US14/964,289 patent/US20160199455A1/en not_active Abandoned
-
2016
- 2016-08-11 AU AU2016213822A patent/AU2016213822B2/en active Active
- 2016-10-26 JP JP2016209535A patent/JP6385410B2/ja active Active
-
2017
- 2017-11-15 JP JP2017220060A patent/JP6641340B2/ja active Active
- 2017-11-30 AU AU2017268648A patent/AU2017268648B2/en active Active
-
2018
- 2018-02-14 CY CY20181100182T patent/CY1119919T1/el unknown
- 2018-07-25 IL IL260769A patent/IL260769B/en active IP Right Grant
-
2019
- 2019-02-07 US US16/270,302 patent/US11266720B2/en active Active
- 2019-04-29 AU AU2019202969A patent/AU2019202969A1/en not_active Abandoned
- 2019-11-07 JP JP2019202433A patent/JP2020019821A/ja not_active Withdrawn
-
2021
- 2021-05-07 AU AU2021202912A patent/AU2021202912B2/en active Active
- 2021-06-28 HR HRP20211010TT patent/HRP20211010T1/hr unknown
- 2021-07-07 CY CY20211100615T patent/CY1124888T1/el unknown
-
2022
- 2022-01-28 US US17/587,941 patent/US20220265780A1/en active Pending
- 2022-02-14 JP JP2022020759A patent/JP7244688B2/ja active Active
-
2023
- 2023-03-09 JP JP2023036392A patent/JP2023071969A/ja active Pending
-
2024
- 2024-10-30 AU AU2024227757A patent/AU2024227757A1/en active Pending
-
2025
- 2025-03-10 JP JP2025037046A patent/JP2025083451A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512678A5 (enExample) | ||
| JP2013534426A5 (enExample) | ||
| JP2022051964A5 (enExample) | ||
| JP2012529296A5 (enExample) | ||
| CN102906120B (zh) | 重组人g-csf二聚体及其在治疗神经系统疾病中的用途 | |
| EA021425B1 (ru) | Мутанты fgf21 и их применение | |
| EP2823823B1 (en) | Polypeptides for the preparation of drugs for treatment or prevention of rheumatoid arthritis | |
| KR20060023968A (ko) | 중증 급성 호흡기 증후군(ｓａｒｓ)의 치료를 위한 조성물및 방법 | |
| JP2014506787A5 (enExample) | ||
| US8501680B2 (en) | Antagonists against interaction of PF4 and RANTES | |
| JP2007536891A5 (enExample) | ||
| EP3647320B1 (en) | Acetylcholine receptor-binding peptide | |
| CN118922544A (zh) | Ebv相关恶性肿瘤特异性适配体及其在癌症成像和治疗中的用途 | |
| US20230055021A1 (en) | Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics | |
| JP7016125B2 (ja) | 脳梗塞の治療薬 | |
| RU2851806C1 (ru) | Композиции и способы их применения для лечения амиотрофического латерального склероза (als) | |
| Overton et al. | Engineered gcn4 trimerization motif | |
| WO2024236297A1 (en) | Engineered gcn4 trimerization motif | |
| AU2024274462A1 (en) | Engineered gcn4 trimerization motif | |
| EP4648789A1 (en) | Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating adverse post-ischemic cardiac remodeling in a patient who experienced a myocardial infarction | |
| JP5439007B2 (ja) | 血管内皮細胞増殖因子阻害剤及び抗癌剤 | |
| CN101469028A (zh) | 肿瘤坏死因子受体-免疫球蛋白的融合蛋白用于肺癌药物的用途 | |
| HK1160650A (en) | Antagonists against interaction of pf4 and rantes |